Matthew Mangzhu Zhao

USPTO Granted Patents = 15 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 19(Granted Patents)

Location History:

Edison, PA (US) (2005)
Edison, NJ (US) (2002 - 2021)

Company Filing History:

10 out of 86

Lexicon Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

patents

Years Active: 2002-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12344596 - Solid forms of (S)-1-((2',6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof (2025-07-01),

2. 12312325 - Methods and compounds useful in the synthesis of an AAK1 inhibitor (2025-05-27),

3. 10968192 - Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis (2021-04-06),

4. 9067962 - Methods of treating diabetes (2015-06-30),

5. 8772483 - Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid (2014-07-08),

6. 8450532 - Compounds useful in the preparation of tryptophan hydroxylase inhibitors (2013-05-28),

7. 8293878 - Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors (2012-10-23),

8. 8217156 - Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use (2012-07-10),

9. 8026347 - Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors (2011-09-27),

10. 7897763 - Process for the preparation of substituted phenylalanines (2011-03-01),

11. 7875642 - Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1 (2011-01-25),

12. 6924291 - Process for making spiro isobenzofuranone compounds (2005-08-02),

13. 6872724 - Polymorphs with tyrosine kinase activity (2005-03-29),

14. 6600040 - Process for the synthesis of (2R, 2-alpha-R, 3A)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1, 4-oxazine (2003-07-29),

15. 6395898 - Trans-glycosidation process for the synthesis of (2R, 2-alpha-R, 3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine (2002-05-28),

Title: **Matthew Mangzhu Zhao: A Pioneer in AAK1 Inhibitor Research**

Introduction

Matthew Mangzhu Zhao, based in Edison, NJ, is a prominent inventor renowned for his contributions in pharmacology, particularly in the development of AAK1 inhibitors. With a remarkable portfolio of 15 patents, Zhao has been at the forefront of pharmaceutical innovations, paving the way for new therapeutic options.

Latest Patents

Zhao’s latest patents include “Solid forms of (S)-1-((2',6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof” and “Methods and compounds useful in the synthesis of an AAK1 inhibitor.” These inventions detail the formulations and preparation methods for AAK1 inhibitors, focusing on their solid forms and pharmaceutical applications.

Career Highlights

Throughout his career, Matthew Zhao has worked with reputable organizations such as Lexicon Pharmaceuticals, Inc. and Merck & Company, Inc. His innovative research has significantly impacted the realm of drug development, particularly in creating compounds that effectively inhibit AAK1, a target for various therapeutic interventions.

Collaborations

Collaboration has been key to Zhao’s success as an inventor. He has worked alongside esteemed colleagues such as Wenxue Wu and Haiming Zhang, contributing to advancements in the synthesis and formulation of pharmaceutical compounds. These partnerships have enriched the quality and efficacy of their collective research output.

Conclusion

Matthew Mangzhu Zhao's work exemplifies the vital role of inventors in advancing science and medicine. With numerous patents attributed to his name, he continues to push the boundaries of pharmaceutical innovation. His contributions to AAK1 inhibitor research not only demonstrate his ingenuity as an inventor but also showcase the potential to improve patient outcomes through innovative therapies.

This text is generated by artificial intelligence and may not be accurate.